Elshazly et al. analyzed the changes in the percentage of atherosclerotic volume and major adverse cardiovascular events at 2 years at different levels of Remnant-C from 5,754 patients with coronary heart disease who underwent an intravascular ultrasound, indicating that Remnant-C is positively associated with the progression of coronary atherosclerosis volume in ASCVD patients treated with statins, independent of dyslipidemia, C-reactive protein or clinical risk factors (18). The gene discussed is CRP; the disease is coronary atherosclerosis.